Jan 09, 2020
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jan 08, 2020
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Jan 06, 2020
Mirati Therapeutics Announces Executive Management Changes
Nov 04, 2019
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
Oct 23, 2019
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Oct 17, 2019
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Aug 15, 2019
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
Aug 05, 2019
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
Jul 09, 2019
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
Jun 27, 2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Jun 25, 2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jun 24, 2019
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Apr 29, 2019
Mirati Therapeutics Reports First Quarter 2019 Financial Results
Apr 01, 2019
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
Feb 07, 2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
Jan 22, 2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Jan 16, 2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jan 16, 2019
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
Jan 15, 2019
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
Jan 07, 2019
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)